JUBILANT DRAXIMAGE RADIOPHARMACIES, INC.

Jubilant DraxImage Radiopharmacies, Inc. specializes in the manufacturing and delivery of radiopharmaceuticals for nuclear medicine applications, with a focus on diagnostic and therapeutic radioisotopes used in clinical imaging and targeted radiation therapy. The company’s technical expertise lies in GMP-compliant radiopharmaceutical synthesis, radiolabeling of pharmaceutical agents, quality control of short-lived isotopes, and cold kit formulation for on-site reconstitution at VA medical facilities. Their capability includes end-to-end production of technetium-99m-based agents, fluorodeoxyglucose (FDG), and other PET/SPECT tracers, ensuring compliance with USP <825> and FDA cGMP standards for sterile, radioactive drug products. A key differentiator is their ability to support time-sensitive, just-in-time delivery schedules critical to nuclear medicine departments with limited on-site radiopharmaceutical production capacity. The contractor maintains a consistent and exclusive relationship with the Department of Veterans Affairs, supplying radiopharmaceuticals across multiple VA medical centers for nuclear imaging and therapeutic protocols. Their work supports routine diagnostic procedures such as cardiac stress testing, oncologic staging, and bone scans, with recurring delivery orders indicating long-term, mission-critical partnership. The VA relies on this contractor for reliable, high-purity radiopharmaceuticals that meet stringent radiological safety and dosimetry requirements. The primary NAICS code 325412 reflects core competency in pharmaceutical preparation manufacturing, specifically in radiopharmaceuticals—a niche vertical requiring specialized infrastructure, radiation shielding, and licensed personnel. The company is positioned as a trusted supplier within the federal nuclear medicine supply chain, serving a highly regulated and technically demanding segment of the healthcare market. Jubilant DraxImage is headquartered in Norcross, Georgia, and operates as an 8H entity under federal contracting rules. While no formal government certifications are listed, their sustained performance with the VA underscores operational readiness and regulatory adherence in the radiopharmaceutical space.